We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has AbCellera Biologics Inc. (ABCL - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AbCellera Biologics Inc. is one of 919 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AbCellera Biologics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABCL's full-year earnings has moved 25.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ABCL has moved about 137.1% on a year-to-date basis. In comparison, Medical companies have returned an average of 4%. This means that AbCellera Biologics Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Agilon Health (AGL - Free Report) . The stock has returned 544.8% year-to-date.
For Agilon Health, the consensus EPS estimate for the current year has increased 44.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AbCellera Biologics Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 440 individual stocks and currently sits at #150 in the Zacks Industry Rank. Stocks in this group have gained about 9.3% so far this year, so ABCL is performing better this group in terms of year-to-date returns.
Agilon Health, however, belongs to the Medical Services industry. Currently, this 72-stock industry is ranked #99. The industry has moved +1.4% so far this year.
Investors with an interest in Medical stocks should continue to track AbCellera Biologics Inc. and Agilon Health. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has AbCellera Biologics Inc. (ABCL - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AbCellera Biologics Inc. is one of 919 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AbCellera Biologics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABCL's full-year earnings has moved 25.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ABCL has moved about 137.1% on a year-to-date basis. In comparison, Medical companies have returned an average of 4%. This means that AbCellera Biologics Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Agilon Health (AGL - Free Report) . The stock has returned 544.8% year-to-date.
For Agilon Health, the consensus EPS estimate for the current year has increased 44.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AbCellera Biologics Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 440 individual stocks and currently sits at #150 in the Zacks Industry Rank. Stocks in this group have gained about 9.3% so far this year, so ABCL is performing better this group in terms of year-to-date returns.
Agilon Health, however, belongs to the Medical Services industry. Currently, this 72-stock industry is ranked #99. The industry has moved +1.4% so far this year.
Investors with an interest in Medical stocks should continue to track AbCellera Biologics Inc. and Agilon Health. These stocks will be looking to continue their solid performance.